Decentralized clinical trials are not an all-or-nothing approach, they encompass a spectrum of hybrid designs that when implemented correctly deliver transformative results. In this white paper, Science 37 leaders discuss where decentralized research is now, and where we are headed. Experts unveil new—and proven— models and the benefits they deliver, from accelerated patient enrollment and improved experience to real-world representation.
Mobile Visits in Decentralized Clinical Trials: The Past, Present and Future
May 7th 2024In March 2024, the US FDA issued its guidance, “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” outlining the agency’s objectives for protecting public health as artificial intelligence (AI) and other technologies become more prevalent in healthcare.
Digital Biomarkers Solution shows pathway to reduced clinical trial sample sizes, shorter durations
April 5th 2024Digital biomarkers provide a pathway to the future where clinical trial sponsors can potentially benefit from reduced trial duration and sample size. Learn more about these benefits from a simulated study.